Company Overview and News
KUALA LUMPUR (Oct 8): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 9) may include: UEM Sunrise Bhd, T7 Global Bhd, Reach Energy Bhd, MMC Corp Bhd, Gamuda Bhd, MCE Holdings Bhd and IHH Healthcare Bhd.
5148 5225 7245 Q0F IHHHF 5256 0131 5001
KUALA LUMPUR (Oct 8): Pahang Crown Princess Tengku Datuk Aishah Ahmad Shah has been appointed as the non-executive chairman of Diversified Gateway Solutions Bhd.
7245 0131 5001
KUALA LUMPUR (Aug 7): Datuk Ahmad Nizam Salleh, the newly appointed chairman of Petroliam Nasional Bhd (Petronas), has quit the board of construction and oil and gas outfit, WZ Satu Bhd.
Ahmad Nizam(pic), 63, has worked in Petronas since 1981. From 2010 to 2015, he was the managing director/CEO of South Africa-based Engen Ltd, an 80%-owned subsidiary of Petronas. Engen operates in 20 countries, including in southern Africa and the Indian Ocean islands.
KUALA LUMPUR (July 20): WZ Satu Bhd fell 7.81% this morning after it swung into a net loss of RM7.29 million in the the third quarter ended May 31, 2018 (3QFY18) from a RM8.03 million net profit last year after its three key segments — civil engineering and construction, oil and gas, and mining — all turned into the red.
KUALA LUMPUR (July 19): Based on corporate announcements and news flow today, companies that may be in focus on Friday (July 20) may include the following: AirAsia, AirAsia X, APFT, BAT, CIMB, Malayan Flour Mills, PUC, Serba Dinamik and WZ Satu.
FLY 5238 7245 BATS 4162 SMHS 3662
KUALA LUMPUR (July 19): WZ Satu Bhd swung into a net loss of RM7.29 million for the third quarter ended May 31, 2018 (3QFY18) compared to a net profit of RM8.03 million a year ago, after key segments reported losses.
7245 BSMAF 1818
2018-04-16 thestar.com.my - 1
KUALA LUMPUR: Datasonic Group Bhd , Serba Dinamik Holdings Bhd, MK Land Holdings Bhd , WZ Satu Bhd and Vizione Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.
5216 7245 CSYJY CSYJF 8893 544
KUALA LUMPUR: JF Apex Research expects WZ Satu Bhd , Berjaya Food Bhd, Pestech International Bhd and Zecon Bhd to generate trading interest following their latest corporate news.
5219 7245 5196
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...